Apogee Therapeutics, Inc. (APGE) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is Michael Thomas Henderson.
APGE has IPO date of 2023-07-14, 196 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $4.95B.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
